Millennium Management LLC Has $4.73 Million Holdings in Artivion, Inc. (NYSE:AORT)

Millennium Management LLC lifted its position in shares of Artivion, Inc. (NYSE:AORT) by 25.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,482 shares of the company’s stock after acquiring an additional 33,220 shares during the period. Millennium Management LLC owned approximately 0.39% of Artivion worth $4,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in AORT. Barclays PLC lifted its holdings in shares of Artivion by 346.3% during the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares during the period. KBC Group NV increased its position in shares of Artivion by 80.4% during the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock worth $80,000 after buying an additional 1,254 shares during the period. R Squared Ltd acquired a new stake in shares of Artivion during the fourth quarter worth $39,000. Calamos Advisors LLC grew its holdings in Artivion by 113.7% in the fourth quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock worth $1,802,000 after purchasing an additional 33,541 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Artivion by 3.8% during the fourth quarter. Principal Financial Group Inc. now owns 202,028 shares of the company’s stock valued at $5,776,000 after buying an additional 7,398 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Price Performance

AORT stock opened at $29.72 on Thursday. The stock has a market cap of $1.27 billion, a PE ratio of -1,486.00 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a one year low of $21.97 and a one year high of $32.33. The firm has a 50 day simple moving average of $25.43 and a two-hundred day simple moving average of $27.36.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The business had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Transactions at Artivion

In related news, Director Anthony B. Semedo sold 2,600 shares of the company’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $28.47, for a total transaction of $74,022.00. Following the completion of the sale, the director now directly owns 33,059 shares in the company, valued at $941,189.73. This represents a 7.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 18,020 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares of the company’s stock, valued at $4,655,514.24. This trade represents a 8.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,414 shares of company stock worth $1,716,731. 7.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on AORT shares. JMP Securities reissued a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.